Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease

Joshua Solomon, Maria Carolina Festa, Yiannis S. Chatzizisis, Ratna Samanta, Rita S. Suri, Thomas A. Mavrakanas

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Diabetes drives an increasing burden of cardiovascular and renal disease worldwide, motivating the search for new hypoglycemic agents that confer cardiac and renal protective effects. Although initially developed as hypoglycemic agents, sodium-glucose co-transporter 2 (SGLT-2) inhibitors have since been studied in patients with and without diabetes for the management of heart failure and chronic kidney disease. A growing body of evidence supports the efficacy and safety of SGLT-2 inhibitors in patients with chronic kidney disease (CKD), based on complex mechanisms of action that extend far beyond glucosuria and that confer beneficial effects on cardiovascular and renal hemodynamics, fibrosis, inflammation, and end-organ protection. This review focuses on the pharmacology and pathophysiology of SGLT-2 inhibitors in patients with CKD, as well as their cardiovascular and renal effects in this population. We are focusing on the five agents that have been tested in cardiovascular outcome trials and that have been approved either in Europe or in North America: empagliflozin, dapagliflozin, canagliflozin, ertugliglozin, and sotagliflozin.

Original languageEnglish (US)
Article number108330
JournalPharmacology and Therapeutics
StatePublished - Feb 2023


  • Albuminuria
  • Canagliflozin
  • Cardiovascular events
  • Chronic kidney disease
  • Dapagliflozin
  • Empagliflozin
  • Ertugliflozin
  • Progression
  • Sodium-glucose co-transporter 2 inhibitors
  • Sotagliflozin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease'. Together they form a unique fingerprint.

Cite this